For hepatocellular carcinoma, Sia et al. also identified two subgroups characterized by exhausted or adaptive immune responses to predict the therapeutic effects of PD-1, PD-L1, or transforming growth factor β1 inhibitor [22]. The gene discussed is CD274; the disease is hepatocellular carcinoma.